Wedbush Reiterates Outperform Rating on Blueprint Medicines (BPMC), Adds to Best Idea List

March 24, 2020 6:42 AM EDT
Get Alerts BPMC Hot Sheet
Price: $89.68 +3.09%

Rating Summary:
    13 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 26 | New: 45
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten reiterated an Outperform rating and $122.00 price target on Blueprint Medicines (NASDAQ: BPMC)

  • Adds to Best Idea List

For an analyst ratings summary and ratings history on Blueprint Medicines click here. For more ratings news on Blueprint Medicines click here.

Shares of Blueprint Medicines closed at $51.32 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments